All news

24 NOV 2023

International rollout of the VEOS implant range

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces the accelerated rollout of its range of VEOS implants for intervertebral fixation by posterior approach into new markets.

Press releases
13 NOV 2023

Minutes of the General Meeting of November 10, 2023

An Extraordinary General Mee1ng of Spineway shareholders was held on first no1ce on Friday, November 10, 2023 at 9:30 a.m. at the company’s registered office, 7 allée Moulin Berger in Ecully (69)

Press releases
07 NOV 2023

Appointment of Sandrine Carle as Deputy Chief Executive Officer

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces the appointment of Sandrine Carle as Deputy Chief Executive Officer. Ms. Carle joined Spineway in July 2022, at the time of the acquisition of Spine Innovations, where she was CEO. She was instrumental in the successful integration of Spine Innovations into the Spineway Group.

Press releases
06 NOV 2023

VEOS system well perceived at the NASS 2023 conference in the United States / Sales growth in France

Spineway Group, specialists in innovative implants for the treatment of severe spinal pathologies, is pleased to announce that its VEOS posterior spinal fixation system received an excellent response from the spine implant industry at the North American Spine Society (NASS) Congress in Los Angeles last October1.

Press releases
19 OCT 2023

Spineway obtains 510(k) clearance from the FDA for its VEOS spinal fixation system

Spineway Group, a specialist in innovative implants for the treatment of severe spinal conditions, is pleased to announce the recent 510(k) clearance from the US Food and Drug Administration (FDA) for its VEOS Spinal Fixation System.

Press releases
13 OCT 2023

9-month revenue up 40% at €7.5 million

Spineway recorded revenue of €2.1 million in the third quarter of 2023, taking the 9-month total to €7.5 million, a 40% increase compared with 2022. Revenue growth over the first 9 months was driven mainly by sales by Spine Innovations, consolidated in July 2022. As announced, third-quarter revenue was automatically impacted by a less favorable impact from change in scope.

Press releases
26 SEPT 2023

H1 2023 results

The Board of Directors of Spineway, meeting on September 18, 2023, under the chairmanship of Stéphane Le Roux, approved the financial statements for the six months to June 30, 2023.

Press releases
14 SEPT 2023

Spineway organizes an international masterclass with expert spine surgeons

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, announces that its Spineway Academy department, with the support of GECO1(Groupe d’études de la Chirurgie Osseuse – Bone Surgery Study Group) and its SAC (Spine Arthroplasty Community) working group, has organized a masterclass on cervical and lumbar disc prostheses with French and international surgeons. This event was held on September 9 in Behoust (France) and focused on total disc replacement using prostheses.

Press releases
11 JULY 2023

First-half 2023 revenue of €5.4 million (+75%)

Spineway’s total revenue for the first half of 2023 was €5.4 million, up 75% compared with the first half of 2022. Growth was driven mainly by the contribution of sales of Spine Innovations, acquired in July 2022. However, organic growth1 remained sustained, representing 12% in the first half of 2023, thanks to the steep increase in Distimp sales (+66%), demonstrating the momentum spurred by the Group’s commercial activity over the period.

Press releases
LOADING